Patents by Inventor Rashid Bux

Rashid Bux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230251261
    Abstract: A biomarker panel and method for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Inventors: Rashid Bux, Daniel Sitar
  • Patent number: 11656229
    Abstract: A biomarker panel for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof. A biomarker panel for a serum test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, C10:2, PC aa C32:2, PC ae C36:0, and PC ae C44:5; and lysoPC a C18:2, or a combination thereof.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: May 23, 2023
    Assignee: BioMark Cancer Systems Inc.
    Inventors: Rashid Bux, Daniel Sitar
  • Publication number: 20230069827
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 9, 2023
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Patent number: 11441168
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: September 13, 2022
    Assignee: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Publication number: 20220260573
    Abstract: A biomarker panel for discriminating lung cancer comprises the biomarkers valine, lysoPhosphatidylcholine acyl C18:2 (Lyso PC a18:2), decadienyl-L-carnitine (C10:2) phosphatidylcholine, acyl-alkyl C36:0 (PC aa C36:0), phosphatidylcholine diacyl C30:2 (PC aa C30:2), spermine, and diacetylspermine.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 18, 2022
    Inventor: Rashid Bux
  • Publication number: 20220033875
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 3, 2022
    Applicant: BioMark Technologies Inc.
    Inventors: Brian CHENG, Rashid BUX, Daniel SITAR
  • Publication number: 20220003769
    Abstract: A biomarker panel for a serum test for detecting lung cancer, wherein the biomarkers are selected from the group of biomarkers consisting of arginine, C18.2, decadienylcamitine (C10:2), LYSOC18.2, methionine, ornithine, PC32:2AA, PC36.0AA, PC36.0AE, putrescine, spermidine, spermine, and valine. The serum test for diagnosing lung cancer may account for smoking history.
    Type: Application
    Filed: December 23, 2019
    Publication date: January 6, 2022
    Applicant: BioMark Cancer Systems Inc.
    Inventor: Rashid Bux
  • Patent number: 10175226
    Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: January 8, 2019
    Assignee: BioMark Technologies, Inc.
    Inventors: Reuven Gordon, Brian Cheng, Rashid Bux, Bram Ramjiawan, Aftab Ahmed, Fraser Alan Hof
  • Publication number: 20180180618
    Abstract: A biomarker panel for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof. A biomarker panel for a serum test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, C10:2, PC aa C32:2, PC ae C36:0, and PC ae C44:5; and lysoPC a C18:2, or a combination thereof.
    Type: Application
    Filed: June 27, 2016
    Publication date: June 28, 2018
    Applicant: BioMark Cancer Systems Inc.
    Inventors: Rashid Bux, Daniel Sitar
  • Publication number: 20170328881
    Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 16, 2017
    Applicant: BioMark Technologies, Inc.
    Inventors: Reuven Gordon, Brian Cheng, Rashid Bux, Bram Ramjiawan, Aftab Ahmed, Fraser Alan Hof
  • Publication number: 20170209272
    Abstract: Elevated levels of spermidine/spermine N1-acetyltransferase (SSAT) gene expression expression were observed in breast, prostate and lung cancer cell lines. Elevated levels of SSAT gene expression were verified in tissues from patients with breast, prostate and lung cancer. Elevated SSAT gene expression is elevated in different human cancers and elevated SSAT gene expression may accordingly serve as a companion diagnostic biomarker for detection and monitoring of cancer progression.
    Type: Application
    Filed: June 9, 2015
    Publication date: July 27, 2017
    Applicant: BioMark Technologies Inc.
    Inventors: Rashid Bux, Brian Cheng, Paramjit S. Tappia, Bram Ramjiawan
  • Publication number: 20160041145
    Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicant: BIOMARCK TECHNOLOGIES INC.
    Inventors: Reuven Gordon, Brian Cheng, Rashid Bux, Bram Ramjiawan, Aftab Ahmed, Fraser Alan Hof
  • Publication number: 20160017054
    Abstract: An anti-cancer drug compound comprises a spermidine/spermine N1-acetyltransferase antibody. The spermidine/spermine N1-acetyltransferase antibody may be a monoclonal antibody or a polyclonal antibody. A method of treating cancer comprises the use of a spermidine/spermine N1-acetyltransferase antibody. The spermidine/spermine N1-acetyltransferase antibody may be a monoclonal antibody or a polyclonal antibody.
    Type: Application
    Filed: January 30, 2014
    Publication date: January 21, 2016
    Applicant: Biomark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Derek Cheng
  • Publication number: 20150290160
    Abstract: An anti-cancer drug compound comprises an spermidine/spermine N-acetyltransferase substrate. The spermidine/spermine N-acetyltransferase substrate may be a monoamine. The spermidine/spermine N-acetyltransferase substrate may be amantadine, rimantadine, dopamine or L-DOPA. A method of treating cancer comprises the use of an spermidine/spermine N-acetyltransferase substrate to treat cancer. The spermidine/spermine N-acetyltransferase substrate may be a monoamine. The spermidine/spermine N-acetyltransferase substrate may be amantadine, rimantadine, dopamine or L-DOPA.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 15, 2015
    Inventors: Brian Cheng, Rashid Bux, Derek Cheng
  • Publication number: 20140315217
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Publication number: 20140287446
    Abstract: A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 25, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Gregorio Aversa, Bram Ramjiawan, Daniel Sitar